Gossamer Bio Inc. announced that, during the evaluation of the impact of the Prosera trial results on its clinical programs, it has suspended new patient enrollment in the Phase III Seranata study for patients with progressive fibrosing interstitial lung disease (Ph-ILD).

Gossamer Bio Inc. announced that, during the evaluation of the impact of the Prosera trial results on its clinical programs, it has suspended new patient enrollment in the Phase III Seranata study for patients with progressive fibrosing interstitial lung disease (Ph-ILD).

老虎证券2026/03/17 20:25

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

该决定旨在确保临床试验方案与最新数据保持科学一致性。 This decision aims to ensure that the clinical trial protocol remains scientifically consistent with the latest data.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gossamer Bio Inc. announced that, during the evaluation of the impact of the Prosera trial results on its clinical programs, it has suspended new patient enrollment in the Phase III Seranata study for patients with progressive fibrosing interstitial lung disease (Ph-ILD).

You may also like

Trending news

Crypto prices